Sharma SP, Suk KT, Kim DJ. Significance of gut microbiota in alcoholic and non-alcoholic fatty liver diseases. World J Gastroenterol 2021; 27(37): 6161-6179 [PMID: 34712025 DOI: 10.3748/wjg.v27.i37.6161]
Corresponding Author of This Article
Dong Joon Kim, MD, Professor, Institute for Liver and Digestive Diseases, Hallym University College of Medicine, Chuncheon 24252, South Korea. djkim@hallym.ac.kr
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Frontier
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Oct 7, 2021; 27(37): 6161-6179 Published online Oct 7, 2021. doi: 10.3748/wjg.v27.i37.6161
Significance of gut microbiota in alcoholic and non-alcoholic fatty liver diseases
Satya Priya Sharma, Ki Tae Suk, Dong Joon Kim
Satya Priya Sharma, Ki Tae Suk, Dong Joon Kim, Institute for Liver and Digestive Diseases, Hallym University College of Medicine, Chuncheon 24252, South Korea
Author contributions: Suk KT and Kim DJ equally contributed on this manuscript; Sharma SP and Suk KT contributed to manuscript preparation and writing; Sharma SP, Suk KT and Kim DJ conceptualize and design the manuscript, fulfill the authorship criteria established by the International Committee of Medical Journal Editors and verify the validity of the results reported; and the final draft of the manuscript is read and approved by all the authors.
Supported byBasic Science Research Program (National Research Foundation of Korea), No. 2020R1A6A1A03043026.
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Dong Joon Kim, MD, Professor, Institute for Liver and Digestive Diseases, Hallym University College of Medicine, Chuncheon 24252, South Korea. djkim@hallym.ac.kr
Received: May 21, 2021 Peer-review started: May 21, 2021 First decision: June 22, 2021 Revised: July 5, 2021 Accepted: August 31, 2021 Article in press: August 31, 2021 Published online: October 7, 2021
Abstract
Liver-gut communication is vital in fatty liver diseases, and gut microbes are the key regulators in maintaining liver homeostasis. Chronic alcohol abuse and persistent overnutrition create dysbiosis in gut ecology, which can contribute to fatty liver disease. In this review, we discuss the gut microbial compositional changes that occur in alcoholic and nonalcoholic fatty liver diseases and how this gut microbial dysbiosis and its metabolic products are involved in fatty liver disease pathophysiology. We also summarize the new approaches related to gut microbes that might help in the diagnosis and treatment of fatty liver disease.
Core Tip: In this review, we compare the gut microbial composition in two different fatty liver diseases: Alcoholic fatty liver and nonalcoholic fatty liver. This review enables readers to recognize the gut microbiota compositional differences that occur in these two histopathologically analogous conditions and to explore these gut microbial compositional variations in their research. Additionally, this review will also be helpful in the design of new experiments aiming to develop new diagnostic and/or therapeutic methodologies.
